Latest News
June 02, 2025

Successfully completed a Phase 1a study for a US-based Innovator Biotech Company!

  Successfully completed a Phase 1a study for a US-based Innovator Biotech Company! Key highlights FPI achieved in 90 days from award Completed 6 cohorts (23 patients) in 9 months Type of study: Phase 1a Dose Escalation Study Therapeutic Area: Oncology (Solid Tumors) Country of Trial Execution: USA CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Mark Kirschbaum Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas ASCO25 OncologyResearch ClinicalTrials CBCCGlobalResearch InnovationInHealthcare